Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genova's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 46.44.
Genova's Days Inventory for the
six
months ended in Mar. 2026 was 4.34.
Genova's Days Payable for the
six
months ended in Mar. 2026 was 23.4.
Therefore, Genova's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 27.38.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Genova Cash Conversion Cycle Related Terms
Genova Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Genova's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9341 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Genova's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genova Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Genova's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Genova's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Genova's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genova (TSE:9341) has a Cash Conversion Cycle of 27.38 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Genova and its competitors.
Is Genova's Cash Conversion Cycle too high?
Genova's current Cash Conversion Cycle is 27.38. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.14. Genova's value of 27.38 is 82.7% below this industry median. Overall, Genova has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genova's Cash Conversion Cycle compare to ABT and SYK?
Genova's Cash Conversion Cycle of 27.38 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.14. Genova's value of 27.38 is 82.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.14, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genova's current Cash Conversion Cycle of 27.38 is 82.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Genova and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genova's current Cash Conversion Cycle is 27.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genova stock overvalued right now?
Based on GuruFocus' analysis, Genova (TSE:9341) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,961.82, compared to a current price of 円611.00 — trading 68.9% below its estimated fair value. The current Cash Conversion Cycle is 27.38 and 82.7% below the Medical Devices & Instruments industry median of 158.14. Genova's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Genova (TSE:9341), the current Cash Conversion Cycle is 27.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genova (TSE:9341) Overvalued in 2026?
Based on GuruFocus' analysis, Genova stock appears to be undervalued.
The current stock price of 円611.00 is trading 68.9% below its estimated GF Value™ of 円1,961.82.
GuruFocus considers Genova to be Possible Value Trap.
Key valuation signals for TSE:9341:
Cash Conversion Cycle: 27.38
GF Value™: 円1,961.82 vs. price of 円611.00 (68.9% below fair value)
Industry Position: 82.7% below the Medical Devices & Instruments median
No single metric tells the full story. See the TSE:9341 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genova Inc manages operations of the medical information site and sales of automatic reception and payment machines for clinics. The group operates in two reportable segments: Medical Platform Business and the Smart Clinic Project. The majority of its revenue is generated from the Medical Platform Business, which operates an online media site (Medical Dock) that provides preventive information and health knowledge to users (patients) on diseases and symptoms. In addition, it also supports users in finding a family doctor that suits them. The Smart Clinic Business develops and provides services that improve the convenience and efficiency of non-medical procedures at medical institutions.
77GF Score
Get the complete analysis for TSE:9341
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9341 has been successfully added to your 
